Alzheimer’s disease (AD) is a neurodegenerative disease with unknown pathogenesis and complex pathological manifestations. At present, a large number of studies on targeted drugs for the typical pathological phenomenon of AD (Aβ) have ended in failure. Although there are some drugs on the market that indirectly act on AD, their efficacy is very low and the side effects are substantial, so there is an urgent need to develop a new strategy for the treatment of AD. An increasing number of studies have confirmed epigenetic changes in AD. Although it is not clear whether these epigenetic changes are the cause or result of AD, they provide a new avenue of treatment for medical researchers worldwide. This article summarizes various epigenetic changes in AD, including DNA methylation, histone modification and miRNA, and concludes that epigenetics has great potential as a new target for the treatment of AD.
CITATION STYLE
Gao, X., Chen, Q., Yao, H., Tan, J., Liu, Z., Zhou, Y., & Zou, Z. (2022, June 23). Epigenetics in Alzheimer’s Disease. Frontiers in Aging Neuroscience. Frontiers Media S.A. https://doi.org/10.3389/fnagi.2022.911635
Mendeley helps you to discover research relevant for your work.